Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies
Open Access

Risk Factors and Clinical Significance of Grade ≥3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer

RYO SATO, YUKIHIRO YOSHIMI, TETSUHARU NISHIO, YU MATSUNAGA and RIKIYA MATSUMOTO
In Vivo May 2026, 40 (3) 1628-1636; DOI: https://doi.org/10.21873/invivo.14313
RYO SATO
1Department of Urology, Chutoen General Medical Center, Kakegawa, Japan;
2Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rsato0202uro{at}gmail.com
YUKIHIRO YOSHIMI
1Department of Urology, Chutoen General Medical Center, Kakegawa, Japan;
2Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TETSUHARU NISHIO
1Department of Urology, Chutoen General Medical Center, Kakegawa, Japan;
2Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU MATSUNAGA
1Department of Urology, Chutoen General Medical Center, Kakegawa, Japan;
2Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RIKIYA MATSUMOTO
1Department of Urology, Chutoen General Medical Center, Kakegawa, Japan;
2Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 40 no. 3 1628-1636
DOI 
https://doi.org/10.21873/invivo.14313
PMID 
42049400

Published By 
International Institute of Anticancer Research
Print ISSN 
0258-851X
Online ISSN 
1791-7549
History 
  • Received January 23, 2026
  • Revision received February 25, 2026
  • Accepted February 27, 2026
  • Published online April 28, 2026.

Copyright & License 
Copyright © 2026 The Author(s). Published by the International Institute of Anticancer Research. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Author Information

  1. RYO SATO1,2⇑,
  2. YUKIHIRO YOSHIMI1,2,
  3. TETSUHARU NISHIO1,2,
  4. YU MATSUNAGA1,2 and
  5. RIKIYA MATSUMOTO1,2
  1. 1Department of Urology, Chutoen General Medical Center, Kakegawa, Japan;
  2. 2Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan
  1. Ryo Sato, Department of Urology, Chutoen General Medical Center, 1-1 Shobugaike, Kakegawa, Japan. Tel: +81 537215555, e-mail: rsato0202uro{at}gmail.com
View Full Text

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

In Vivo: 40 (3)
In Vivo
Vol. 40, Issue 3
May-June 2026
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Ed Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Risk Factors and Clinical Significance of Grade ≥3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Risk Factors and Clinical Significance of Grade ≥3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer
RYO SATO, YUKIHIRO YOSHIMI, TETSUHARU NISHIO, YU MATSUNAGA, RIKIYA MATSUMOTO
In Vivo May 2026, 40 (3) 1628-1636; DOI: 10.21873/invivo.14313

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Risk Factors and Clinical Significance of Grade ≥3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer
RYO SATO, YUKIHIRO YOSHIMI, TETSUHARU NISHIO, YU MATSUNAGA, RIKIYA MATSUMOTO
In Vivo May 2026, 40 (3) 1628-1636; DOI: 10.21873/invivo.14313
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Signal Detection Analysis of Hypnotic-induced Respiratory Depression
  • Development and Validation of an EHR-based Algorithm for Identifying Pneumocystis jirovecii Pneumonia
  • Safety and Efficacy of SOX Therapy After Preoperative Chemoradiotherapy for Advanced Lower Rectal Cancer: A Phase I Study
Show more Clinical Studies

Keywords

  • Metastatic castration-resistant prostate cancer
  • cabazitaxel
  • neutropenia
  • pegfilgrastim
  • primary prophylaxis
In Vivo

© 2026 In Vivo

Powered by HighWire